Tag: bromsmedicin

Pressmeddelanden

Gilead Files European Marketing Application for Boosting Agent Cobicistat

2012-05-24 14:01 Gilead Science Gilead Sciences, Inc. (Nasdaq: GILD) announced today that the Marketing Authorisation Application (MAA) for cobicistat, submitted on April 26, 2012, has been validated by the European Medicines Agency (EMA).

FDA ADVISORY COMMITTEE SUPPORTS APPROV AL OF GILEAD’S TRUVADA® FOR REDUCING THE RISK OF ACQUIRING HIV

2012-05-11 16:37 Gilead Science

Gilead Announces Sustained Virologic Response Data for 12-Week Regimen of GS-7977 Plus Pegylated Interferon and Ribavirin in Genotype 1 Hepatitis C Patients

2012-04-27 14:24 Gilead Science - ATOMIC Data Demonstrate High Cure Rates in Genotype 1 Patients With 12 Weeks of Treatment -

Gilead Announces Early Sustained Virologic Response Rates for GS-7977 Plus Ribavirin in Genotype 1 Treatment-Na ïve Hepatitis C Patients

2012-04-27 14:23 Gilead Science - Interim Results Reported from ELECTRON and QUANTUM Studies -

U.S. Food and Drug Administration Approves New Formulations of Viread® for Use by Children Living With HIV

2012-04-11 08:54 Gilead Science -- Viread Now Available in an Oral Powder and Three Lower-Strength Tablets --

U.S. FDA Accepts New Drug Application for Gilead's Once-Daily, Single-Tablet Quad HIV Regimen

2012-04-02 14:51 Gilead Science

Gilead Files European Marketing Application for the Quad, a Once-Daily Single-Tablet Regimen for the Treatment of HIV Infection

2012-04-02 14:50 Gilead Science Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the Marketing Authorisation Application (MAA) for the Quad single-tablet regimen of elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults, submitted on November 24, 2011, has been validated by the European Medicines Agency (EMA).

Gileads nya behandling för hiv-1-INFEKTION SOM tas som en tablett en gång om dagen – finns nu i sverige

2012-04-02 09:06 Gilead Science Gilead Sciences, Inc. (Nasdaq: GILD) meddelade i dag att Eviplera® (emtricitabin/rilpivirin/tenofovirdisoproxil), en komplett behandling för HIV-1-infektion som tas som en tablett en gång dagligen, nu finns tillgänglig i Sverige och resten av Norden.

Gilead Sciences Submits Supplemental New Drug Application to U.S. Food and Drug Administration for Truvada® for Reducing the Risk of Acquiring HIV

2012-03-26 10:21 Gilead Science - If Approved, Product Would Represent First Antiretroviral Indicated to Reduce Risk of HIV Infection in Adults -

Gilead Announces Two-Year Data From Pivotal Phase 3 Study of Elvitegravir, an Integrase Inhibitor for HIV

2012-03-26 10:19 Gilead Science - Company to Submit U.S. Regulatory Filing for Elvitegravir in Second Quarter of 2012 -